PŘEHLEDOVÉ ČLÁNKY Akutní poškození ledvin vlivem antimikrobiální terapie | 233 / Vnitř Lék. 2022;68(4):227-233 / VNITŘNÍ LÉKAŘSTVÍ www.casopisvnitrnilekarstvi.cz 5. Bentley ML, Corwin HL, Dasta J. Drug‑induced acute kidney injury in the critically ill adult: Recognition and prevention strategies. Crit Care Med 2010; 38(6 Suppl.): S169–S174 6. Perazella MA, Markowitz GS. Drug‑induced acute interstitial nephritis. Nat. Rev. Nephrol. 2010, 6, 461–470. [Google Scholar] [CrossRef ] [PubMed] 7. Mulligan MJ, Cobbs CG. Bacteriostatic versus bactericidal activity. Infect Dis Clin North Am. 1989 Sep;3(3):389-98. PMID: 2671128. 8. Norrby SR. Neurotoxicity of carbapenem antibacterials. Drug Saf. 1996 Aug;15(2):8790. doi: 10.2165/00002018-199615020-00001. PMID: 8884160. 9. Krause KM, Serio AW, Kane TR et al. Aminoglycosides: An Overview. Cold Spring Harb Perspect Med. 2016 Jun 1;6(6):a027029. doi: 10.1101/cshperspect.a027029. PMID: 27252397; PMCID: PMC4888811. 10. Drew R. Aminoglycosides, doi: https://www.uptodate.com/contents/aminoglycosides?c si=caef2e4f-8240-441a-9b16-ad0d 8542df77 & source=contentShare 11. Humes HD. Aminoglycoside nephrotoxicity. Kidney Int 1988; 33:900. 12. McWilliam SJ, Antoine DJ, Smyth RL, et. al. Aminoglycoside‑induced nephrotoxicity in children. Pediatr Nephrol. 2017;32:2015-25. 13. Denamur S, Boland L, Beyaert M et al. Subcellular mechanisms involved in apoptosis induced by aminoglycoside antibiotics: Insights on p53, proteasome and endoplasmic reticulum. Toxicol Appl Pharmacol. 2016;309:24-36. 14. Martinez‑Salgado C, Rodríguez‑Barbero A, Eleno N et al. Gentamicin induces Jun ‑AP1 expression and JNK activation in renal glomeruli and cultured mesangial cells. Life Sci. 2005;77:2285-98. 15. Drew R, Sakoulas G. Vancomycin: Parenteral dosing, monitoring, and adverse effects in adults, doi: https://www.uptodate.com/contents/vancomycin‑parenteral ‑dosing‑monitoring‑and‑adverse‑effects‑in‑adults?csi=aaaf3a27-9cc2-461e-9987b7c4170e7c41 & source=contentShare 16. Elyasi S, Khalili H, Dashti‑Khavidaki S et al. Vancomycin‑induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol. 2012;68:1243-55. 17. Sinha Ray A, Haikal A, Hammoud KA, Yu AS. Vancomycin and the Risk of AKI: A Systematic Review and Meta‑Analysis. Clin J Am Soc Nephrol. 2016 Dec 7;11(12):2132-2140. doi: 10.2215/CJN.05920616. Epub 2016 Nov 28. PMID: 27895134; PMCID: PMC5142072. 18. Sawada A, Kawanishi K, Morikawa S et. al. Biopsy‑proven vancomycin‑induced acute kidney injury: a case report and literature review. BMC Nephrol. 2018 Mar 27;19(1):72. doi: 10.1186/s12882-018-0845-1. PMID: 29587650; PMCID: PMC5872390. 19. Petejova N, Martinek A, Zahalkova J et. al. Vancomycin removal during low‑flux and high‑flux extended daily hemodialysis in critically ill septic patients. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012 Dec;156(4):342-7. doi: 10.5507/bp.2012.002. Epub 2012 Jan 30. PMID: 22660225. 20. Cai Y, Lee W, Kwa AL. Polymyxin B versus colistin: an update. Expert Rev Anti Infect Ther. 2015;13(12):1481-97. doi: 10.1586/14787210.2015.1093933. Epub 2015 Oct 21. PMID: 26488563. 21. MacLaren G, Spelman D. Polymyxins: An overview, doi: https://www.uptodate.com/ contents/polymyxins‑an‑overview?csi=119451e1-13c2-436d-810c-7ec1fdfad5f1 & source= contentShare 22. Lima LM, Silva BNMD, Barbosa G et al. β‑lactam antibiotics: An overview from a medicinal chemistry perspective. Eur J Med Chem. 2020 Dec 15;208:112829. doi: 10.1016/j. ejmech.2020.112829. Epub 2020 Sep 16. PMID: 33002736. 23. González E, Gutiérrez E, Galeano C et al. Early steroid treatment improves the recovery of renal function in patients with drug‑induced acute interstitial nephritis. Kidney Int. 2008;73:940-6. 24. Burgess LD, Drew RH. Comparison of the incidence of vancomycin‑induced nephrotoxicity in hospitalized patients with and without concomitant piperacillintazobactam. Pharmacotherapy. 2014;34:670-6. 25. Gomes DM, Smotherman C, Birch A et al. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin‑tazobactam or cefepime. Pharmacotherapy. 2014;34:662-9. 26. Navalkele B, Pogue JM, Karino S et al. Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin‑Tazobactam Compared to Those on Vancomycin and Cefepime. Clin Infect, DiS. 2017;64:116- 23. 27. Mansoor GA, Panner BJ, Ornt DB. Azithromycin‑induced acute interstitial nephritis. Ann Intern Med 1993;119:636-7. 28. Persico C, Rocchi A, Edefonti A et. al. The acute interstitial nephritis induced by azithromycin. NDT Plus. 2011;4:218. 29. Woodruff AE, Meaney CJ, Hansen EA et. al. Azithromycin‑Induced, Biopsy‑Proven Acute Interstitial Nephritis in an Adult Successfully Treated with Low‑Dose Corticosteroids. Pharmacotherapy. 2015;35:e169-74. 30. Russell W, SmithW. Clarithromycin‑induced acute interstitial nephritis andminimal change disease. NDT Plus. 2009;2:382-3. 31. Gandhi S, Fleet JL, Bailey DG et. al. Calcium‑channel blocker‑clarithromycin drug interactions and acute kidney injury. JAMA. 2013;310:2544-53. 32. Mishima E, Maruyama K, Nakazawa T et. al. Acute Kidney Injury from Excessive Potentiation of Calcium‑channel Blocker via Synergistic CYP3A4 Inhibition by Clarithromycin Plus Voriconazole. Intern Med. 2017;56:1687-90 33. Drlica K, ZhaoX. DNAgyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997 Sep;61(3):377-92. doi: 10.1128/mmbr.61. 3. 377-392.1997. PMID: 9293187; PMCID: PMC232616. 34. Bolon B. Mini‑Review: Toxic Tendinopathy. Toxicol Pathol. 2017 Oct;45(7):834-837. doi: 10.1177/0192623317711614. Epub 2017 May 28. PMID: 28553748. 35. Bird ST, Etminan M, Brophy JM, et. al. Risk of acute kidney injury associated with the use of fluoroquinolones. CMAJ. 2013;185:E475-82. 36. Muriithi AK, Leung N, Valeri AM et al. Biopsy‑proven acute interstitial nephritis, 19932011: a case series. Am J Kidney, DiS. 2014;64:558-66. 37. Khan M, Ortega LM, Bagwan N et. al. Crystal‑induced acute kidney injury due to ciprofloxacin. J Nephropathol. 2015;4:29-31. 38. Li Y, Zhu Y, Zhong Q et al. Serious Adverse Reactions From Anti‑tuberculosis Drugs Among 599 Children Hospitalized for Tuberculosis. Pediatr Infect Dis J. 2017;36:720-5. 39. Wortham JM, Goggin M, Mora C et. al. Acute kidney injury during treatment for latent tuberculous infection with rifampin. Int J Tuberc Lung, DiS. 2017;21:596-7. 40. Chang CH, Chen YF, Wu VC et al. Acute kidney injury due to anti‑tuberculosis drugs: a five‑year experience in an aging population. BMC Infect, DiS. 2014;14:23. 41. Drew R, Sterling T. Antituberculous drugs: An overview, doi: https://www.uptodate. com/contents/antituberculous‑drugs‑an‑overview?search=antimyco bacterials & source=- search_result & selectedTitle=1~150 & usage_type=default & display_rank=1 42. Rhodes A, Evans LE, Alhazzani W et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017 Mar;43(3):304-377. doi: 10.1007/s00134-017-4683-6. Epub 2017 Jan 18. PMID: 28101605.
RkJQdWJsaXNoZXIy NDA4Mjc=